Opens in a new tab

Trichomoniasis (Trich): Symptoms, Test, Treatment and Prevention

Table of Content

Friendly doctor talking with a smiling couple in a bright clinic, with a urine sample cup, swab test kit and a pill bottle on the desk

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

Trichomoniasis, often called "trich," is a common sexually transmitted infection (STI) caused by a tiny parasite, Trichomonas vaginalis. It is curable with prescription pills. Most people never notice symptoms: the CDC estimates that 70% to 85% of infected people have minimal or no genital symptoms, which is why trich spreads so easily. When symptoms do appear, women may have itching, burning and a thin, frothy or yellow-green discharge with a fishy smell, while men may feel irritation inside the penis or burning after urinating or ejaculating.

The most accurate trichomoniasis test is a nucleic acid amplification test (NAAT) on a vaginal swab or a urine sample. The 2021 CDC STI Treatment Guidelines recommend metronidazole 500 mg twice a day for 7 days for women and a single 2 g dose for men, with treatment of every current sex partner and a new test for women about 3 months later, because reinfection is common.

Key takeaways

  • Trich is caused by a parasite, not a bacterium, and it does not go away on its own. Without treatment, it can last for months or even years.
  • Symptoms, when present, usually start 5 to 28 days after exposure, but many people never have any. Symptoms alone cannot confirm the diagnosis: a lab test is needed.
  • NAATs find trich in 95% to 100% of infected women. A wet mount (microscope slide) misses about a third to half of infections.
  • Women take metronidazole for 7 days; men usually take one 2 g dose. Partners must be treated at the same time, and about 1 in 5 people are reinfected within 3 months.
  • Untreated trich is linked to preterm birth, low birth weight and a 1.5-fold higher risk of getting HIV. Treatment is safe during pregnancy.

What is trichomoniasis?

Trichomoniasis is an infection of the genital tract by Trichomonas vaginalis, a single-celled parasite (a protozoan) that moves with small whip-like tails. Cleveland Clinic stresses that it is a parasite and not a bacterium, which explains why it is treated with a specific family of medicines, the 5-nitroimidazoles, rather than with the antibiotics used for chlamydia.

It is the most common nonviral STI in the world. The World Health Organization (WHO) estimates that there were about 156 million new infections among people aged 15 to 49 in 2020. In the United States, the CDC estimated more than 2 million infections in 2018. The 2021 CDC guidelines report a prevalence of 2.1% in women and 0.5% in men, with large health disparities: 9.6% among Black women and 3.6% among Black men. The CDC adds that older women are more likely to be infected than younger women.

How trich spreads

Trich spreads mainly through vaginal sex without a condom, from penis to vagina or vagina to vagina. People without symptoms can pass it on. Cleveland Clinic notes that it is not spread through food, drinks, kissing or holding hands.

Risk factors

A 2025 meta-analysis of 425 studies found a global prevalence of about 8%, with higher rates among people who smoke, use drugs or do not use condoms (odds ratio 1.67), and among people with another STI such as HIV, herpes or chlamydia (odds ratio 2.01). The CDC lists multiple sex partners, transactional sex, drug misuse, a past STI and a history of incarceration as reasons to consider screening in women.

Trichomoniasis symptoms

Symptoms range from mild irritation to severe inflammation, and they can come and go. According to the CDC, about 70% of infected people have no symptoms at all, so many infections are found only by screening.

Symptoms in women

  • A thin discharge that can be white, yellowish or greenish, often frothy, with a fishy smell. WHO reports that more than half of symptomatic women have a vaginal discharge.
  • Itching, burning, redness or soreness of the genitals, sometimes with swollen labia in severe cases.
  • Discomfort or pain when urinating, which can mimic a urinary tract infection.
  • Pain during sex.
  • During a pelvic exam, a clinician may see tiny red spots on the cervix, called a "strawberry cervix."

Burning and discharge have many possible causes, including yeast infections and bacterial vaginosis. Our guide to vaginal burning: causes, tests and next steps explains how doctors tell them apart.

Symptoms in men

Most men with trich have no symptoms, but they can still infect their partners. WHO estimates that only about 10% of infected men have urethritis (inflammation of the urethra) or a urethral discharge. When symptoms occur, they include itching or irritation inside the penis, burning after urinating or ejaculating, a frequent urge to urinate and a frothy discharge from the penis. These signs overlap with those of gonorrhea and chlamydia, so men with urethral symptoms are usually tested for all three.

Incubation period

The CDC and MedlinePlus state that symptoms usually appear 5 to 28 days after infection, but they can appear much later or never. Because the parasite can persist for months or years without treatment, a new positive test does not always mean a recent infection or an unfaithful partner.

How trichomoniasis is diagnosed

You cannot diagnose trich from symptoms or appearance alone. The CDC recommends testing women who have a vaginal discharge, women with HIV at least once a year, and considering yearly screening for people at higher risk. A trichomoniasis test is often ordered together with tests for chlamydia, gonorrhea, syphilis and HIV, because these infections often occur together.

Before a swab or urine test, MedlinePlus advises avoiding douches and vaginal creams for 24 hours. Swabs are taken from the vagina or cervix in women and from the urethra in men, and urine samples can also be tested. The CDC does not recommend rectal or oral testing for trich.

Types of trichomoniasis test

  • NAAT (molecular test): detects the parasite's genetic material in a vaginal swab, endocervical swab or urine. This is the most sensitive option and works in women and men, depending on the assay.
  • Rapid antigen test: detects parasite proteins in vaginal fluid in 10 to 15 minutes. It is used in clinics but is not reliable for men.
  • Wet mount: a drop of vaginal fluid is looked at under a microscope to see moving parasites. It is quick and cheap but misses many infections, especially if the slide is not read within an hour.
  • Culture: the sample is grown in a special medium and checked daily for up to a week. It is less sensitive than a NAAT but is needed when doctors want to test whether the parasite resists metronidazole.

Trich is sometimes reported on a standard urine test. If your report mentions trichomonads, white blood cells or leukocyte esterase in urine, your doctor will usually confirm the finding with a NAAT. Our urinalysis results guide explains the rest of the report.

Trichomoniasis test accuracy: reference table

The table below summarizes the performance of the main tests reported in the 2021 CDC guidelines. Sensitivity is the share of infected people the test finds; specificity is the share of uninfected people correctly reported as negative. These results are percentages and times, so they read the same in US and SI units.

TestSampleSensitivity / specificityTime to result
Aptima TV NAATFemale samples (FDA-cleared for women only)95.3-100% / 95.2-100%Lab, usually days
BD ProbeTec TV Qx NAATFemale samples (FDA-cleared for women only)98.3% / 99.6%Lab, usually days
Xpert TV NAATFemale swabs, female and male urine99.5-100% / 99.4-99.9%About 1 hour
OSOM rapid antigen testVaginal fluid (not for men)82-95% / 97-100%10-15 minutes
Solana rapid testVaginal swab or urineOver 98% (vaginal), over 92% (urine)Under 40 minutes
Wet mount microscopyVaginal fluid44-68% sensitivity (about 20% if read after 1 hour)Minutes
Culture (InPouch)Vaginal fluid, urine or discharge44-75% sensitivityRead daily for 5 days within 7 days
Visby at-home PCR test (FDA, 2025)Self-collected vaginal swab97.8% of positives and 98.5% of negatives correctly identifiedAbout 30 minutes

How to read your trichomoniasis test results

A positive NAAT, rapid test, culture or wet mount means the parasite was found, and you need treatment. Because NAATs are so specific, a positive result is very rarely wrong. Your recent sex partners should be told so they can be treated, and you should be tested for other STIs.

A negative NAAT makes infection unlikely. A negative wet mount, on the other hand, does not rule out trich: MedlinePlus notes that other, more sensitive tests may be ordered. If you were treated recently, the CDC advises waiting at least 3 weeks after treatment before a NAAT retest.

At-home trichomoniasis tests

Two kinds of at-home trichomoniasis test exist. Mail-in kits let you collect urine or a vaginal swab at home and send it to a lab, often with tests for chlamydia and gonorrhea. In March 2025, the FDA also authorized the first over-the-counter test that gives results at home: the Visby Medical Women's Sexual Health Test, a self-collected vaginal swab analyzed by a small powered device in about 30 minutes. For trichomoniasis, it correctly identified 97.8% of positive samples and 98.5% of negative samples. The FDA advises seeing a health care provider after a positive result, and also after a negative result if you have symptoms or a recent exposure.

Trichomoniasis treatment

Trich is treated with oral 5-nitroimidazole medicines. ChEMBL describes how metronidazole works: it generates free radicals that damage the DNA of the parasite. The 2021 CDC regimens are:

WhoRecommended regimenNotes
Women (including during pregnancy)Metronidazole 500 mg (0.5 g) by mouth twice daily for 7 daysSame regimen for women with HIV
MenMetronidazole 2 g by mouth in a single doseSame for men with HIV
Alternative (women and men)Tinidazole 2 g by mouth in a single doseAvoid in pregnancy
Other FDA-approved optionSecnidazole 2 g, one packet mixed into soft foodNot given in pregnancy; not among the 2021 CDC regimens

According to the CDC, cure rates are about 84% to 98% with metronidazole and 92% to 100% with tinidazole. The CDC does not recommend metronidazole vaginal gel for trich. Common side effects include a metallic taste and nausea; Merck Manual adds that some women develop a vaginal yeast infection afterward.

Why women need 7 days of metronidazole

For years, women also received a single 2 g dose. This changed after a randomized trial of 623 women published in The Lancet Infectious Diseases in 2018: 4 weeks after treatment, 11% of women in the 7-day group still had trich, compared with 19% in the single-dose group (relative risk 0.55). Side effects were similar in both groups, with nausea the most common (23%). The CDC adopted the 7-day regimen for all women in 2021. For men, evidence is more limited, and the single 2 g dose remains the preferred treatment.

Alcohol and metronidazole

Older advice told people to avoid alcohol completely during treatment. The 2021 CDC guidelines reviewed the evidence and found no convincing proof of a dangerous "disulfiram-like" reaction, concluding that refraining from alcohol while taking metronidazole or tinidazole is unnecessary. Ask your pharmacist if you have other reasons to limit alcohol.

Partner treatment and avoiding sex

All current sex partners should be treated at the same time, even if they have no symptoms. A review by Muzny and colleagues found that up to 70% of male partners of infected women can be infected. Merck Manual advises treating partners from the past 60 days and the most recent partner. Where state law allows, expedited partner therapy (EPT) lets your clinician give you medicine or a prescription for your partner without a separate visit. The CDC advises avoiding sex until you and your partners have been treated and symptoms have gone; Cleveland Clinic suggests waiting about a week after finishing treatment.

Retesting after treatment

About 1 in 5 people are reinfected within 3 months, most often by an untreated partner. The CDC recommends that all sexually active women be retested about 3 months after treatment, whether or not their partners were treated; if that is not possible, at the next visit within 12 months. Data are too limited to recommend routine retesting in men.

Persistent infection and drug resistance

Most "treatment failures" are really reinfections. True resistance to metronidazole occurs in about 4% to 10% of cases, and to tinidazole in about 1%, according to the CDC. If infection persists without reexposure, doctors may prescribe another regimen, order a culture for susceptibility testing through the CDC, and involve an infectious disease specialist. People with a true allergy to these drugs can usually be desensitized to metronidazole under an allergist's care.

Trichomoniasis in pregnancy

A 2021 meta-analysis of 19 studies in BJOG found that trich during pregnancy is linked to preterm delivery (odds ratio 1.27), prelabor rupture of membranes (odds ratio 1.87) and low birth weight, under 2,500 g or about 5.5 lb (odds ratio 2.12). The CDC recommends testing and treating pregnant women who have symptoms, at any stage of pregnancy. Routine screening of pregnant women without symptoms has no proven benefit, so it is not recommended for everyone.

Metronidazole is considered low risk in pregnancy and is given as the same 7-day course. Tinidazole and secnidazole should be avoided. While breastfeeding, metronidazole is considered compatible, although some clinicians suggest pausing for 12 to 24 hours; after tinidazole, breastfeeding should be paused for 72 hours. Trich testing is one of many checks that may happen during prenatal care; see our guide to blood tests during pregnancy.

Trichomoniasis, HIV and other health risks

Trich causes genital inflammation, which makes it easier to catch or pass on other infections. A 2019 meta-analysis of 11 studies found that people with trich were 1.5 times more likely to acquire HIV. The CDC reports that up to 53% of women with HIV also have trich, so women with HIV should be screened when they enter care and at least once a year, and treated with the 7-day regimen, which worked better than the single dose in this group. Our overview of HIV and AIDS: symptoms, testing and treatment explains HIV testing and prevention options.

The CDC also notes an association with cervical cancer (about 2.1-fold higher risk in a meta-analysis), and WHO links trich to a higher risk of pelvic inflammatory disease. Trich does not replace regular cervical screening; read what a normal Pap with a positive HPV test means to understand your Pap and HPV results.

How to prevent trichomoniasis

  • Use external or internal condoms correctly every time you have vaginal sex. WHO calls consistent and correct condom use the most effective way to prevent sexual transmission.
  • Limit the number of partners, or keep a mutually monogamous relationship with a partner who has tested negative.
  • Get tested if you have symptoms, a new partner or a partner with an STI, and get a full STI panel, including a serology test for syphilis and HIV.
  • After treatment, wait until both partners are cured before having sex again, and book the 3-month retest.
  • Do not count on doxycycline post-exposure prophylaxis (doxy-PEP): a 2026 analysis found it did not prevent trich in women.

Trich often travels with other STIs. If you test positive, ask about testing for syphilis and genital herpes if you have sores.

When to see a doctor

See a doctor, a sexual health clinic or a family planning clinic if you:

  • Have an unusual vaginal or penile discharge, genital itching, burning or pain when urinating or during sex.
  • Learn that a partner has trich or another STI, even if you feel fine.
  • Get a positive result on an at-home test, or a negative one despite symptoms.
  • Are pregnant and have genital symptoms.
  • Still have symptoms after finishing treatment.

Call 911 or go to an emergency department if you are pregnant and have fluid leaking from the vagina, regular contractions or bleeding before 37 weeks, or if you have severe pelvic or belly pain with fever. These signs need urgent care whatever their cause.

Latest scientific advances in trichomoniasis

The first over-the-counter home test with results in 30 minutes (2025)

In March 2025, the FDA granted marketing authorization to the Visby Medical Women's Sexual Health Test, the first test sold without a prescription that detects chlamydia, gonorrhea and trichomoniasis at home. It correctly identified 97.8% of trich-positive and 98.5% of trich-negative samples. In emergency departments, molecular point-of-care STI testing is also spreading: a 2026 study at an urban US hospital found that it shortened stays by 76 minutes and allowed treatment matched to the infection. What it means for you: a positive home result still needs a prescription and partner treatment.

Pap tests can be a useful clue (2026)

Pap tests are not considered diagnostic for trich, mainly because of historically low sensitivity. A 2026 study of 200 liquid-based Pap tests reported as showing trich found that all 200 were confirmed by NAAT, a positive predictive value of 100%. Yet only 4.8% of patients had a confirmatory test and only 53.2% were treated within 2 months. What it means for you: if your Pap report mentions trichomonas, ask your clinician for a NAAT or treatment rather than ignoring it.

A single-dose option for women and men under study (2025-2029)

Even with the 7-day regimen, 9% to 11% of women still test positive at the test of cure, and the best treatment for men is uncertain. Secnidazole, a long-acting nitroimidazole, cured 92.2% of women versus 1.5% with placebo in a phase 3 trial (NCT03935217). A large US trial, NCT06261840, started in 2025 and plans to enroll 1,200 women and men to compare single-dose secnidazole with 7-day metronidazole, with results expected after 2029. What it means for you: a one-time dose may become a guideline choice for both sexes if this trial confirms it works as well.

Drug resistance is being watched closely (2026)

A 2026 meta-analysis of 16 studies estimated that about 14.8% of tested T. vaginalis samples worldwide showed resistance to metronidazole, with very large differences between studies. US data used by the CDC remain lower, at about 4% to 10%. What it means for you: finish every dose, make sure your partner is treated, and return if symptoms persist so a culture can check for resistance.

Testing in pregnancy: what trials show (2024)

A large cluster randomized trial in Papua New Guinea (WANTAIM, 4,526 women) tested pregnant women on the spot for chlamydia, gonorrhea, trich and bacterial vaginosis and treated them immediately. Preterm birth or low birth weight occurred in 18.8% with testing versus 17.8% with standard care, so universal testing did not improve these outcomes overall. What it means for you: in the US, testing remains focused on pregnant women with symptoms or risk factors, and treatment of a confirmed infection is still recommended.

Which tests can help?

If you have genital symptoms or a new partner, the most useful tests are a trichomonas NAAT on a vaginal swab or urine, along with NAATs for chlamydia and gonorrhea, and blood tests for HIV and syphilis. Your doctor may also check vaginal fluid for yeast and bacterial vaginosis. In men with urethral symptoms, a urine NAAT for trich, chlamydia and gonorrhea is standard.

A urinalysis that mentions trichomonads or white blood cells is a good reason to ask for a targeted test. Women should plan a NAAT retest about 3 months after treatment.

Glossary

  • Trichomonas vaginalis: the single-celled parasite that causes trichomoniasis.
  • NAAT: nucleic acid amplification test, a molecular test that detects the parasite's genetic material; the most accurate test for trich.
  • Wet mount: a quick microscope exam of vaginal fluid that looks for moving parasites; it misses many infections.
  • Sensitivity: the percentage of infected people a test correctly identifies.
  • Specificity: the percentage of uninfected people a test correctly reports as negative.
  • 5-nitroimidazoles: the family of medicines that treat trich: metronidazole, tinidazole and secnidazole.
  • Expedited partner therapy (EPT): giving medicine or a prescription for a partner without a separate exam.
  • Test of cure: a test done after treatment to check that the infection has cleared.
  • Strawberry cervix: small red spots on the cervix that can be seen in some women with trich.

Frequently asked questions

Can trichomoniasis be diagnosed with a false positive Pap smear?

A Pap test is not a diagnostic test for trich. The CDC says a Pap result showing trich should be confirmed with a test and treated if confirmed. With modern liquid-based Pap tests, false positives seem rare: in a 2026 study, all 200 Pap tests reported as showing trich were confirmed by NAAT.

How does trichomoniasis affect pregnancy?

Untreated trich is linked to preterm delivery, early rupture of the membranes and low birth weight. Pregnant women with symptoms should be tested and treated at any stage. Metronidazole for 7 days is considered safe in pregnancy; tinidazole and secnidazole are avoided.

What is the incubation period for trichomoniasis?

When symptoms appear, they usually start 5 to 28 days after infection. Many people never develop symptoms, and some notice them much later.

How long can trichomoniasis be dormant in a woman or a man?

Trich does not truly go dormant, but it can live quietly without symptoms. Without treatment, the infection can last months or even years in women. Men more often have no symptoms, but they can still carry and pass on the parasite. A positive test therefore does not prove when or from whom the infection came.

Is trichomoniasis curable?

Yes. It is the most common curable STI. Metronidazole cures about 84% to 98% of cases and tinidazole about 92% to 100%. Because reinfection is common, partners must be treated and women should be retested at 3 months.

Is trichomoniasis a bacteria?

No. Trich is caused by a parasite, a protozoan called Trichomonas vaginalis. That is why antibiotics used for chlamydia or gonorrhea do not cure it, and why it needs a nitroimidazole medicine.

Is trichomoniasis very bad, and can it kill you?

Trich is not considered a deadly infection, and it rarely causes long-term problems when treated. Left untreated, however, it raises the risk of getting HIV by about 1.5 times and is linked to pregnancy complications, so it should always be treated.

Can I drink alcohol while taking metronidazole for trich?

The 2021 CDC guidelines found no convincing evidence of a dangerous reaction and state that avoiding alcohol during metronidazole or tinidazole treatment is unnecessary.

Sources

  • Workowski KA et al. — Sexually Transmitted Infections Treatment Guidelines, 2021: Trichomoniasis — Centers for Disease Control and Prevention, 2021 — cdc.gov
  • Workowski KA et al. — Sexually Transmitted Infections Treatment Guidelines, 2021 — MMWR Recomm Rep, 2021 — doi.org
  • Centers for Disease Control and Prevention — Sexually Transmitted Infections Treatment Guidelines, 2021: Bacterial vaginosis (alcohol and metronidazole) — CDC, 2021 — cdc.gov
  • Centers for Disease Control and Prevention — About trichomoniasis — CDC — cdc.gov
  • Kissinger P et al. — Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial — Lancet Infect Dis, 2018 — doi.org
  • Kissinger PJ et al. — Diagnosis and management of Trichomonas vaginalis: summary of evidence reviewed for the 2021 CDC STI Treatment Guidelines — Clin Infect Dis, 2022 — doi.org
  • Muzny CA, Van Gerwen OT, Kissinger P — Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity — Curr Opin Infect Dis, 2020 — doi.org
  • Muzny CA et al. — Efficacy and safety of single oral dosing of secnidazole for trichomoniasis in women: a phase 3, randomized, double-blind, placebo-controlled trial — Clin Infect Dis, 2021 — doi.org
  • Muzny CA, Van Gerwen OT — Secnidazole for trichomoniasis in women and men — Sex Med Rev, 2022 — doi.org
  • Muzny CA et al. — Refining Trichomonas vaginalis treatment in women and men: protocol for a randomised comparison of multi-dose oral metronidazole versus single-dose oral secnidazole — BMJ Open, 2026 — doi.org
  • ClinicalTrials.gov — Refining treatment options for Trichomonas vaginalis infection in women and men (NCT06261840) — Tulane University — clinicaltrials.gov
  • Van Gerwen OT et al. — Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis — BJOG, 2021 — doi.org
  • Masha SC et al. — Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis — Sex Transm Infect, 2019 — doi.org
  • Mulhem E et al. — Clinical utility of Trichomonas vaginalis reported on cervical cytology — J Low Genit Tract Dis, 2026 — doi.org
  • Faizi F et al. — Global prevalence of 5-nitroimidazole resistance in Trichomonas vaginalis: a systematic review and meta-analysis — Infect Disord Drug Targets, 2026 — doi.org
  • Riddell MA et al. — Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-resource settings (WANTAIM) — Lancet Glob Health, 2024 — doi.org
  • Sesay FA et al. — Trichomonas vaginalis among cisgender women taking doxycycline postexposure prophylaxis — J Infect Dis, 2026 — doi.org
  • Dashler G et al. — Real-world use of molecular point-of-care testing for STIs in the emergency department — Open Forum Infect Dis, 2026 — doi.org
  • Tian W et al. — Systematic review and meta-analysis of the global prevalence and infection risk factors of Trichomonas vaginalis — Parasite, 2025 — doi.org
  • US Food and Drug Administration — FDA grants marketing authorization for first home test for chlamydia, gonorrhea and trichomoniasis — FDA, 2025 — fda.gov
  • MedlinePlus — Trichomoniasis test — National Library of Medicine — medlineplus.gov
  • World Health Organization — Trichomoniasis fact sheet — WHO — who.int
  • Merck Manual Consumer Version — Trichomoniasis — Merck & Co — merckmanuals.com
  • Cleveland Clinic — Trichomoniasis — Cleveland Clinic — clevelandclinic.org
  • ChEMBL — Metronidazole (CHEMBL137): mechanism of action — EMBL-EBI — ebi.ac.uk

Further reading

Understand your lab results with AI DiagMe

An STI panel, a urinalysis or a Pap report can be hard to read: trichomonads, leukocytes, leukocyte esterase, NAAT results and HIV or syphilis serology all appear in different places. AI DiagMe reads your lab report in minutes, explains each result in plain language, highlights what needs follow-up, such as a retest 3 months after treatment, and suggests questions to ask your doctor. Upload your lab results to AI DiagMe for a clear, personal report.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practicing hospital physicians in specialties such as hematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr. Claude Tchonko is a hematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specializes in the management of hematologic malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimization of care pathways in onco-hematology.

    Author of a reference work, “Lymphoid Hematologic Malignancies in Mali”, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Hematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Hematology and an inter-university diploma (DIU) in Onco-Hematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming Soon